# Fluge et al. (2019) - Rituximab Phase III Trial for ME/CFS

## Summary

**CRITICAL NEGATIVE TRIAL** - High-quality phase III RCT demonstrating rituximab is ineffective for ME/CFS.

## Citation

Fluge Ã˜, Rekeland IG, Lien K, et al. B-Lymphocyte Depletion in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. *Ann Intern Med*. 2019;170(9):585-593. doi:10.7326/M18-1451

## Key Result

**NO BENEFIT** - Rituximab 26% response vs Placebo 35% response (P=0.22)

## Why This Matters

1. **Definitively refutes** B-cell depletion as ME/CFS treatment
2. **Contradicts earlier studies** showing this is why phase III trials are essential
3. **High placebo response (35%)** shows need for rigorous controls
4. **Significant toxicity** without benefit = harmful treatment

## PDF Status

PDF not openly available (Annals of Internal Medicine subscription required)

## Integration Status

- [x] Abstract saved
- [x] Notes created
- [x] Key findings documented
- [ ] Added to references.bib
- [ ] Added to Appendix H
- [ ] Integrated into treatment chapter

## Certainty: HIGH

- Phase III RCT
- Double-blind, placebo-controlled
- Multicenter (5 hospitals)
- Adequate sample size (n=151)
- Published in top-tier journal (Ann Intern Med)
- Publicly funded (no industry bias)

## Files in This Folder

- `abstract.txt` - Full abstract from PubMed
- `notes.md` - Detailed methodology and results
- `key-findings.md` - Clinical implications and integration guidance
- `README.md` - This file
